Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Current Deferred Revenue: 2019

Historic Current Deferred Revenue for Pharming Group N.V (PHAR) over the last 1 years, with Dec 2019 value amounting to -$1.6 million.

  • Pharming Group N.V's Current Deferred Revenue was N/A to -$1.6 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$1.6 million, marking a year-over-year change of. This contributed to the annual value of -$1.6 million for FY2019, which is N/A change from last year.
  • Latest data reveals that Pharming Group N.V reported Current Deferred Revenue of -$1.6 million as of FY2019.
  • Pharming Group N.V's Current Deferred Revenue's 5-year high stood at -$1.6 million during FY2019, with a 5-year trough of -$1.6 million in FY2019.
  • For the 1-year period, Pharming Group N.V's Current Deferred Revenue averaged around -$1.6 million, with its median value being -$1.6 million (2019).